Desensitization with rituximab for preformed anti-donor antibody and antibody-mediated rejection in kidney transplantation.

Desensitization with rituximab for preformed anti-donor antibody and antibody-mediated rejection in kidney transplantation. - Desensitization with rituximab for preformed anti-donor antibody and antibody-mediated rejection in kidney transplantation.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032113

Enrollment

Registered

2018-04-05

Start date

2008-05-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end stage renal disease

Interventions

200mg of rituximab will given twice intravenously for each patient. Rituximab will reduce to 100mg for pediatric patients.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with preformed anti-donor antibody and/or antibody-mediated rejection

Exclusion criteria

Exclusion criteria: active infection

Design outcomes

Primary

Measure	Time frame
value of anti-donor antibody	—

Secondary

Measure	Time frame
kidney graft function	—

Countries

Japan

Contacts

Public ContactMichio Nojima

Hyogo College of Medicine Department of Urology

nojimam@hyo-med.ac.jp0798-45-6366

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026